Breaking News

ProBioGen, Granite Bio Enter mAb Development and Mfg. Pact

ProBioGen will support the development of Granite Bio's monoclonal antibody pipeline and lead candidate.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Granite Bio, a Swiss biotech company, and ProBioGen entered a Master Services Agreement to support the development of Granite Bio’s mAb pipeline.   Granite Bio’s lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. By using the DirectedLuck transposase, ProBioGen can efficiently start cell line development with multiple candidates, from which one selected candidate will finally be further pursued in CMC activities. Based on ProBi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters